{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T15:07:06Z","timestamp":1793545626685,"version":"4.5.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2014,7,1]],"date-time":"2014-07-01T00:00:00Z","timestamp":1404172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Reumatolog\u00eda Cl\u00ednica"],"published-print":{"date-parts":[[2014,7]]},"DOI":"10.1016\/j.reuma.2013.11.009","type":"journal-article","created":{"date-parts":[[2014,1,3]],"date-time":"2014-01-03T21:01:24Z","timestamp":1388782884000},"page":"210-217","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Eficiencia de la combinaci\u00f3n naproxeno\/esomeprazol para el tratamiento de la artrosis en Espa\u00f1a"],"prefix":"10.1016","volume":"10","author":[{"given":"Margarita","family":"Capel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jes\u00fas","family":"Tornero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Luis","family":"Zamorano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Itziar","family":"Oyag\u00fcez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel \u00c1ngel","family":"Casado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaqu\u00edn","family":"S\u00e1nchez-Covisa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1ngel","family":"Lanas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.reuma.2013.11.009_bib0005","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1136\/ard.60.11.1040","article-title":"The burden of musculoskeletal diseases in the general population of Spain: Results from a national survey","volume":"60","author":"Carmona","year":"2001","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reuma.2013.11.009_bib0010","series-title":"Gu\u00eda de Actuaci\u00f3n en Atenci\u00f3n Primaria","first-page":"1018","article-title":"Artrosis","author":"Garcia","year":"2002"},{"key":"10.1016\/j.reuma.2013.11.009_bib0015","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1002\/art.24214","article-title":"Economic burden of knee and hip osteoarthritis in Spain","volume":"61","author":"Loza","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.reuma.2013.11.009_bib0020","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1136\/ard.2003.011742","volume":"62","author":"Jordan","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reuma.2013.11.009_bib0025","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1002\/1529-0131(200009)43:9<1905::AID-ANR1>3.0.CO;2-P","article-title":"Recommendations for the medical management of the arthritis of the knee and the hip: 2000 update","volume":"43","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.reuma.2013.11.009_bib0030","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S1699-258X(05)72711-X","article-title":"Primer documento de consenso de la Sociedad Espa\u00f1ola de Reumatolog\u00eda sobre el tratamiento farmacol\u00f3gico de la artrosis de rodilla","volume":"1","author":"Alonso","year":"2005","journal-title":"Reumatol Clin"},{"key":"10.1016\/j.reuma.2013.11.009_bib0035","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.joca.2010.01.013","article-title":"OARSI recommendations for the management of hip and knee osteoarthritis. Part III: Changes in evidence following systematic cumulative update of research published through January 2009","volume":"18","author":"Zhang","year":"2010","journal-title":"Osteoarthritis Cartilage"},{"issue":"Suppl 1","key":"10.1016\/j.reuma.2013.11.009_bib0040","doi-asserted-by":"crossref","first-page":"17","DOI":"10.2165\/00019053-200119001-00002","article-title":"Healthcare resource utilisation and costs of treating NSAID-associated gastrointestinal toxicity. A multinational perspective","volume":"19","author":"Chevat","year":"2001","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.reuma.2013.11.009_bib0045","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1136\/gut.2011.239848","article-title":"Suboptimal gastroprotective coverage of NSAID use and the risk of upper gastrointestinal bleeding and ulcers: An observational study using three European databases","volume":"60","author":"Van Soest","year":"2011","journal-title":"Gut"},{"key":"10.1016\/j.reuma.2013.11.009_bib0050","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1136\/bmj.332.7553.1302","article-title":"Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomized trials","volume":"332","author":"Kearney","year":"2006","journal-title":"BMJ"},{"key":"10.1016\/j.reuma.2013.11.009_bib0055","doi-asserted-by":"crossref","first-page":"237","DOI":"10.2165\/11207150-000000000-00000","article-title":"Naproxen\/esomeprazole fixed-dose combination: For the treatment of arthritic symptoms and to reduce the risk of gastric ulcers","volume":"28","author":"Dhillon","year":"2011","journal-title":"Drugs Aging"},{"key":"10.1016\/j.reuma.2013.11.009_bib0060","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1185\/03007995.2011.555756","article-title":"Long-term safety of naproxen and esomeprazole magnesium fixed-dose combination: Phase III study in patients at risk for NSAID-associated gastric ulcers","volume":"27","author":"Sostek","year":"2011","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.reuma.2013.11.009_bib0065","unstructured":"National Collaborating Centre for Chronic Conditions. Osteoarthritis: National clinical guideline for care and management in adults. London: Royal College of Physicians, 2008 [consultado 13 Feb 2013]. Disponible en: http:\/\/www.nice.org.uk\/nicemedia\/live\/11926\/39720\/39720.pdf"},{"key":"10.1016\/j.reuma.2013.11.009_bib0070","doi-asserted-by":"crossref","first-page":"b2538","DOI":"10.1136\/bmj.b2538","article-title":"Cost effectiveness of COX2 selective inhibitors and traditional NSAIDs alone or in combination with a proton pump inhibitor for people with osteoarthritis","volume":"339","author":"Latimer","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.reuma.2013.11.009_bib0075","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1111\/j.1365-2036.2010.04465.x","article-title":"Risk factors for NSAID-associated upper GI clinical events in a long-term prospective study of 34.701 arthritis patients","volume":"32","author":"Laine","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.reuma.2013.11.009_bib0080","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/art.11121","article-title":"The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis","volume":"49","author":"Maetzel","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.reuma.2013.11.009_bib0085","doi-asserted-by":"crossref","first-page":"E118","DOI":"10.1503\/cmaj.081197","article-title":"National trends in rates of death and hospital admissions related to acute myocardial infarction, heart failure and stroke, 1994-2004","volume":"180","author":"Tu","year":"2009","journal-title":"CMAJ"},{"key":"10.1016\/j.reuma.2013.11.009_bib0090","unstructured":"Consejo General de Colegios Oficiales de Farmac\u00e9uticos. Bot plus 2.0 [consultado 14 Nov 2012]. Disponible en: www.portalfarma.com"},{"key":"10.1016\/j.reuma.2013.11.009_bib0095","unstructured":"Ministerio de Sanidad, Servicios Sociales e Igualdad. Conjunto M\u00ednimo B\u00e1sico de Datos. Pesos espa\u00f1oles 2008 (V25) [consultado 14 Nov 2012]. Disponible en: http:\/\/www.msssi.gob.es\/estadEstudios\/estadisticas\/docs\/PESOS_ESPANOLES_AP_GRD_V25_2008.pdf"},{"key":"10.1016\/j.reuma.2013.11.009_bib0100","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S0014-2565(04)71516-7","article-title":"Rofecoxib frente a antiinflamatorios no esteroideos en el tratamiento de la artrosis: an\u00e1lisis coste-efectividad para Espa\u00f1a","volume":"204","author":"Ariza-Ariza","year":"2004","journal-title":"Rev Clin Esp"},{"key":"10.1016\/j.reuma.2013.11.009_bib0105","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1093\/europace\/euq325","article-title":"Predictors of costs related to cardiovascular disease among patients with atrial fibrillation in five European countries","volume":"13","author":"Holstenson","year":"2011","journal-title":"Europace"},{"key":"10.1016\/j.reuma.2013.11.009_bib0110","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/S0300-8932(05)74068-9","article-title":"An\u00e1lisis de la relaci\u00f3n coste-efectividad a corto y largo plazo de clopidogrel a\u00f1adido a terapia est\u00e1ndar en pacientes con s\u00edndrome coronario agudo en Espa\u00f1a","volume":"58","author":"Badia","year":"2005","journal-title":"Rev Esp Cardiol"},{"key":"10.1016\/j.reuma.2013.11.009_bib0115","unstructured":"National Institute for Health and Clinical Excellence. Hypertension: clinical management of primary hypertension in adults. Clinical guidelines GC 127. Appendix I. Cost-effectiveness analysis-pharmacological treatments [consultado 13 Feb 2013]. Disponible en: http:\/\/www.nice.org.uk\/nicemedia\/live\/13561\/56033\/56033.pdf"},{"key":"10.1016\/j.reuma.2013.11.009_bib0120","series-title":"Harrison's Principles of Internal Medicine","first-page":"2828","article-title":"Osteoarthritis","author":"Felson","year":"2012"},{"key":"10.1016\/j.reuma.2013.11.009_bib0125","series-title":"Manual SER de las enfermedades reum\u00e1ticas","first-page":"129","article-title":"AINE y condroprotectores","author":"Arboleya Rodr\u00edguez","year":"2008"},{"key":"10.1016\/j.reuma.2013.11.009_bib0130","first-page":"393","article-title":"Estrategia cl\u00ednica para la prevenci\u00f3n de los efectos adversos sobre el tracto digestivo de los antiinflamatorios no esteroideos","volume":"30","author":"Lanas","year":"2003","journal-title":"Rev Esp Reumatol"},{"key":"10.1016\/j.reuma.2013.11.009_bib0135","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S1699-258X(09)70197-4","article-title":"Uso apropiado de los antiinflamatorios no esteroideos en reumatolog\u00eda: documento de consenso de la Sociedad Espa\u00f1ola de Reumatolog\u00eda y el Colegio Mexicano de Reumatolog\u00eda","volume":"5","author":"Bori","year":"2009","journal-title":"Reumatol Clin"},{"key":"10.1016\/j.reuma.2013.11.009_bib0140","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.reuma.2009.12.009","article-title":"Evaluaci\u00f3n econ\u00f3mica del uso de condroit\u00edn sulfato y antiinflamatorios no esteroideos en el tratamiento de la artrosis. Datos del estudio VECTRA","volume":"6","author":"Rubio-Terr\u00e9s","year":"2010","journal-title":"Reumatol Clin"},{"key":"10.1016\/j.reuma.2013.11.009_bib0145","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0213-9111(03)71688-4","article-title":"An\u00e1lisis coste-efectividad del empleo de celecoxib en el tratamiento de la artrosis","volume":"17","author":"Moreno","year":"2003","journal-title":"Gac Sanit"},{"key":"10.1016\/j.reuma.2013.11.009_bib0150","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/S0213-9111(02)71933-X","article-title":"\u00bfQu\u00e9 es una tecnolog\u00eda sanitaria eficiente en Espa\u00f1a?","volume":"16","author":"Sacrist\u00e1n","year":"2002","journal-title":"Gac Sanit"},{"key":"10.1016\/j.reuma.2013.11.009_bib0155","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1007\/s10198-011-0326-y","article-title":"The use of cost per life year gained as a measurement of cost-effectiveness in Spain: A systematic review of recent publications","volume":"13","author":"Rodr\u00edguez Barrios","year":"2012","journal-title":"Eur J Health Econ"}],"container-title":["Reumatolog\u00eda Cl\u00ednica"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1699258X13002258?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1699258X13002258?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,7]],"date-time":"2018-10-07T13:51:50Z","timestamp":1538920310000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1699258X13002258"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,7]]}},"alternative-id":["S1699258X13002258"],"URL":"https:\/\/doi.org\/10.1016\/j.reuma.2013.11.009","relation":{},"ISSN":["1699-258X"],"issn-type":[{"value":"1699-258X","type":"print"}],"subject":[],"published":{"date-parts":[[2014,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Eficiencia de la combinaci\u00f3n naproxeno\/esomeprazol para el tratamiento de la artrosis en Espa\u00f1a","name":"articletitle","label":"Article Title"},{"value":"Reumatolog\u00eda Cl\u00ednica","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.reuma.2013.11.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Espa\u00f1a, S.L. All rights reserved.","name":"copyright","label":"Copyright"}]}}